Merck Singulair Is Top Asthma Controller In U.S., Headed For $1.2 Bil. Sales
Executive Summary
Merck's asthma drug Singulair (montelukast sodium) appears headed for close to $1.2 bil. in sales for the full year after reaching $675 mil. through the first six months.
You may also be interested in...
Merck Vioxx Sales Will Fall Short Of High Expectations, Firm Says
Merck's Vioxx sales are showing the impact of a slower penetration rate of COX-2 inhibitors into the analgesic market, the company said June 22.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials